

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179	
	Filing Date		2003-07-02	
	First Named Inventor	Kreutzer et al		
	Art Unit	1635		
	Examiner Name	Tracy Ann Vivlemore		
	Attorney Docket Number	A2038-706120		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	Kreutzer et al
Art Unit	1635
Examiner Name	Tracy Ann Vivlemore
Attorney Docket Number	A2038-706120

1	Decision of Board of Appeal in Opposition for EP 114 46 23 (March 29, 2009) (translation attached).	<input checked="" type="checkbox"/>
2	Decision Revoking Patent and Grounds for Decision in Opposition proceedings for EP 1214945 (March 31, 2009).	<input type="checkbox"/>
3	Notice of Opposition by Pfizer against DE 100 80 167.6 (June 19, 2008) (translation attached).	<input checked="" type="checkbox"/>
4	Notice of Opposition by Sanofi Aventis against DE 100 80 167.6 (June 16, 2008).	<input type="checkbox"/>
5	Notice of Opposition by Silence Therapeutics against DE 100 80 167.6 (June 20, 2008).	<input type="checkbox"/>
6	Notice of Opposition by Sima against DE 100 80 167.6 (June 20, 2008).	<input type="checkbox"/>
7	Notice of Opposition by Alexandra Oppl against DE 100 80 167.6 (June 20, 2008).	<input type="checkbox"/>
8	Patentee's Observations submitted by Alnylam Europe AG in Opposition proceedings for DE 100 80 167.6 (December 18, 2008).	<input type="checkbox"/>
9	Written Submission by Alnylam Europe AG in Opposition proceedings for DE 100 80 167.6 (March 4, 2009) (translation attached).	<input checked="" type="checkbox"/>
10	Written Submission by Pfizer in Opposition proceedings for DE 100 80 167.6 (February 27, 2009).	<input type="checkbox"/>
11	Written Submission by Alexandra Oppl in Opposition proceedings for DE 100 80 167.6 (March 4, 2009).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	Kreutzer et al
Art Unit	1635
Examiner Name	Tracy Ann Vivlemore
Attorney Docket Number	A2038-706120

12	Written Submission by SIRNA Therapeutics in Opposition proceedings for DE 100 80 167.6 (March 4, 2009).	<input type="checkbox"/>
13	Patentee's Observations submitted by Alnylam Europe AG in Opposition proceedings for DE 100 66 235.6 (February 4, 2009) (translation attached).	<input checked="" type="checkbox"/>
14	BARLOW et al., "Interferon synthesis in the early post-implantation mouse embryo" Differentiation 27:229-235 (1984).	<input type="checkbox"/>
15	BURKE et al., "Appearance of Interferon Inducibility and Sensitivity during Differentiation of Murine Teratocarcinoma Cells in Vitro" Cell 13:243-248 (1978).	<input type="checkbox"/>
16	HARADA et al., "Absence of the Type I IFN System in EC Cells: Transcriptional Activator (IRF-1) and Repressor (IRF-2) Genes Are Developmentally Regulated" Cell 83:303-312 (1990).	<input type="checkbox"/>
17	NAKAMURA et al., "How Does RNase H recognize a DNA-RNA Hybrid?" Proc. Natl. Acad. Sci. 88:11535-11539 (1991).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.